 |
Raptor Pharmaceutical Corp. to Present at Three Upcoming Investor Conferences
Feb 10, 2012
|
20.2 KB |
|
| |
NOVATO, Calif., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that its Chief Executive Officer, Christopher M. Starr, Ph.D., will present an overview of the Company at three investor conferences in February.
The conference presentation schedule is as follows:
...
|
|
Raptor Pharmaceutical Corp. to Present at the 30th Annual JP Morgan Healthcare Conference
Jan 4, 2012
|
12.3 KB |
|
| |
NOVATO, Calif., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive O...
|
|
Raptor Pharmaceutical Corp. Provides Program Update on RP103 (DR Cysteamine) for Nephropathic Cystinosis
Dec 21, 2011
|
17.0 KB |
|
| |
NOVATO, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced today a program update for its lead investigational compound, RP103...
|
|
Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 (DR Cysteamine Tablets) in Non-Alcoholic Steatohepatitis ("NASH")
Dec 19, 2011
|
19.4 KB |
|
| |
NOVATO, Calif., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the signing of a cooperative research and development agreement ("CRADA") w...
|
|
Raptor Pharmaceutical Corp. to Present at the Oppenheimer 22nd Annual Healthcare Conference
Dec 13, 2011
|
11.3 KB |
|
| |
NOVATO, Calif., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive ...
|
|
Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 9, 2011
|
9.5 KB |
|
| |
NOVATO, Calif., Nov 9, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Ted Daley, President of Raptor will present an overview of the Company at the Lazard Capital Markets 8th Annual Healthcare Conference. Raptor's presentation will take place at The Pierre Hote...
|
|
Raptor Pharmaceutical Corp. Holds Pre-NDA Meeting With FDA for RP103 for Nephropathic Cystinosis
Oct 25, 2011
|
14.0 KB |
|
| |
NOVATO, Calif., Oct 25, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced today that the Company concluded a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration ("FDA") related to its investigational drug candidate, RP103 (delayed-release formulatio...
|
|
Raptor Pharmaceutical Corp. to Present at the BioCentury NewsMakers Conference
Oct 13, 2011
|
9.5 KB |
|
| |
NOVATO, Calif., Oct 13, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Patrick Reichenberger, VP, Commercial Operations of Raptor will present an overview of the Company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference. Raptor's presentation will ...
|
|
Raptor Pharmaceutical Corp. to Present at JMP Securities Healthcare Conference
Sep 22, 2011
|
9.6 KB |
|
| |
NOVATO, Calif., Sep 22, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., co-founder and Chief Executive Officer of Raptor will present an overview of the Company at the JMP Securities Healthcare Conference. Raptor's presentation will ...
|
|
Raptor Pharmaceutical Corp. Announces Closing of Public Offering of Common Stock
Sep 13, 2011
|
12.1 KB |
|
| |
NOVATO, Calif., Sep 13, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the closing of its previously announced underwritten public offering of shares of its common stock at a price to the public of $4.00 per share. The shares sold in the offering included 10,000,000...
|
|
Raptor Pharmaceutical Corp. Announces Pricing of Public Offering of Common Stock
Sep 8, 2011
|
12.1 KB |
|
| |
NOVATO, Calif., Sep 8, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share. The net proceeds to the Company from this offer...
|
|
Raptor Pharmaceutical Corp. Announces Proposed Public Offering of Common Stock
Sep 7, 2011
|
12.0 KB |
|
| |
NOVATO, Calif., Sep 7, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that it intends to offer and sell shares of its common stock, par value $0.001 per share, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purcha...
|
|
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
Jul 25, 2011
|
16.9 KB |
|
| |
NOVATO, Calif., Jul 25, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that its Phase 3 clinical trial of Delayed Release or DR Cysteamine, known as study drug RP103 ("RP103"), for the treatment of nephropathic cystinosis, met the primary endpoint of non-inferiority compar...
|
|
Raptor Pharmaceutical to Host Conference Call and Webcast to Discuss Phase 3 Clinical Trial Results on Tuesday, July 26, 2011 at Noon EDT
Jul 25, 2011
|
11.4 KB |
|
| |
NOVATO, Calif., Jul 25, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced today that they will host a conference call and webcast noon Eastern Time on July 26, 2011, to comment on the Company's positive Phase 3 RP103 clinical trial results.
...
|
|
Raptor Pharmaceutical Receives Notices of Allowance for Two Key Patent Applications Protecting Its Cysteamine Portfolio
Jul 6, 2011
|
16.1 KB |
|
| |
NOVATO, Calif., Jul 6, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the United States Patent and Trademark Office ("USPTO") has issued Notices of Allowance for two patents covering the Company's delayed-release oral formulation of cysteamine bitartrate ("DR C...
|
|
Raptor Pharmaceutical Provides Update on Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis
Jun 6, 2011
|
13.9 KB |
|
| |
NOVATO, Calif., Jun 6, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that on June 3 the last clinical trial patient visits were completed and final data analysis will commence this week on the Phase 3 clinical trial of its delayed-release oral formulation of cystea...
|
|
Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
Apr 13, 2011
|
14.4 KB |
|
| |
NOVATO, Calif., Apr 13, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced today that it has named Kathlene L. Powell to the newly created position of VP, Quality Operations.
Ms. Powell will be responsible for overseeing Quality Assurance and Quality Control (QA/QC)...
|
|
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Apr 13, 2011
|
16.0 KB |
|
| |
NOVATO, Calif., Apr 13, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced today the appointments of Suzanne L. Bruhn, Ph.D., Vijay B. Samant and Timothy P. Walbert to the Company's board of directors. The appointments expand Raptor's Board to eight members.
Christo...
|
|
Raptor Pharmaceutical to Enroll Five Additional Patients in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis
Feb 15, 2011
|
15.2 KB |
|
| |
NOVATO, Calif., Feb 15, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("...
|
|
Raptor Pharmaceutical Completes Enrollment in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis
Jan 24, 2011
|
15.9 KB |
|
| |
NOVATO, Calif., Jan 24, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis (...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz